{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:09:51Z","timestamp":1787584191616,"version":"build-2736575974"},"reference-count":125,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UID\/Multi\/04423\/2019"],"award-info":[{"award-number":["UID\/Multi\/04423\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000035"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000035"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2020,1,17]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Chronic Myeloid Leukemia (CML) represents 15-20% of all new cases of leukemia and is\ncharacterized by an uncontrolled proliferation of abnormal myeloid cells. Currently, the first-line of\ntreatment involves Tyrosine Kinase Inhibitors (TKIs), which specifically inhibits the activity of the fusion\nprotein BCR-ABL. However, resistance, mainly due to mutations, can occur. In the attempt to\nfind more effective and less toxic therapies, several approaches are taken into consideration such as research\nof new anti-leukemic drugs and \u201ccombination chemotherapy\u201d where different drugs that act by\ndifferent mechanisms are used. Here, we reviewed the molecular mechanisms of CML, the main\nmechanisms of drug resistance and current strategies to enhance the therapeutic effect of TKIs in\nCML. Despite major advances in CML treatment, new, more potent anticancer drugs and with fewer\nside effects are needed. Marine organisms, and particularly seaweed, have a high diversity of bioactive\ncompounds with some of them having anticancer activity in several in vitro and in vivo models. The\nstate-of-art suggests that their use during cancer treatment may improve the outcome. We reviewed\nhere the yet few data supporting anti-leukemic activity of some carotenoids and phlorotannins in some\nleukemia models. Also, strategies to overcome drug resistance are discussed, particularly the combination\nof conventional drugs with natural compounds.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557519666190311095655","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T06:54:03Z","timestamp":1552287243000},"page":"39-53","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Bioactive Compounds from Seaweed with Anti-Leukemic Activity: A Mini-Review on Carotenoids and Phlorotannins"],"prefix":"10.2174","volume":"20","author":[{"given":"T\u00e2nia P.","family":"Almeida","sequence":"first","affiliation":[{"name":"Team of Histomorphology, Physiopathology and Applied Toxicology, CIIMAR\/CIMAR - Interdisciplinary Center for Marine and Environmental Research, U.Porto - University of Porto, Avenida General Norton de Matos s\/n, 4450-208 Matosinhos, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice A.","family":"Ramos","sequence":"additional","affiliation":[{"name":"Team of Histomorphology, Physiopathology and Applied Toxicology, CIIMAR\/CIMAR - Interdisciplinary Center for Marine and Environmental Research, U.Porto - University of Porto, Avenida General Norton de Matos s\/n, 4450-208 Matosinhos, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Team of Histomorphology, Physiopathology and Applied Toxicology, CIIMAR\/CIMAR - Interdisciplinary Center for Marine and Environmental Research, U.Porto - University of Porto, Avenida General Norton de Matos s\/n, 4450-208 Matosinhos, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"Azqueta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, University of Navarra, C\/Irunlarrea 1, CP 31008 Pamplona, Navarra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Rocha","sequence":"additional","affiliation":[{"name":"Team of Histomorphology, Physiopathology and Applied Toxicology, CIIMAR\/CIMAR - Interdisciplinary Center for Marine and Environmental Research, U.Porto - University of Porto, Avenida General Norton de Matos s\/n, 4450-208 Matosinhos, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/imj.12135","volume":"43","author":"Gibson J.","year":"2013","unstructured":"Gibson J.; Iland H.J.; Larsen S.R.; Brown C.M.; Joshua D.E.; Leukaemias into the 21st century. Part 2: The chronic leukaemias. Intern Med J 2013,43(5),484-494","journal-title":"Intern Med J"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"Torre L.A.","year":"2015","unstructured":"Torre L.A.; Bray F.; Siegel R.L.; Ferlay J.; Lortet-Tieulent J.; Jemal A.; Global cancer statistics, 2012. CA Cancer J Clin 2015,65(2),87-108","journal-title":"CA Cancer J Clin"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"Vardiman J.W.","year":"2009","unstructured":"Vardiman J.W.; Thiele J.; Arber D.A.; Brunning R.D.; Borowitz M.J.; Porwit A.; Harris N.L.; Le Beau M.M.; Hellstrom-Lindberg E.; Tefferi A.; Bloomfield C.D.; The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009,114(5),937-951","journal-title":"Blood"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1200\/JCO.2014.57.1034","volume":"32","author":"Freireich E.J.","year":"2014","unstructured":"Freireich E.J.; Wiernik P.H.; Steensma D.P.; The leukemias: A half-century of discovery. J Clin Oncol 2014,32(31),3463-3469","journal-title":"J Clin Oncol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"Rowley J.D.","year":"1973","unstructured":"Rowley J.D.; Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973,243(5405),290-293","journal-title":"Nature"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"Ilander M.","year":"2017","unstructured":"Ilander M.; Olsson-Stromberg U.; Schlums H.; Guilhot J.; Bruck O.; Lahteenmaki H.; Kasanen T.; Koskenvesa P.; Soderlund S.; Hoglund M.; Markevarn B.; Sjalander A.; Lotfi K.; Dreimane A.; Lubking A.; Holm E.; Bjoreman M.; Lehmann S.; Stenke L.; Ohm L.; Gedde-Dahl T.; Majeed W.; Ehrencrona H.; Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 2017,31(5),1108-1116","journal-title":"Leukemia"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","volume":"6","author":"Zhou H.","year":"2015","unstructured":"Zhou H.; Xu R.; Leukemia stem cells: The root of chronic myeloid leukemia. Protein Cell 2015,6(6),403-412","journal-title":"Protein Cell"},{"key":"ref=8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1180","volume":"8","author":"Carter B.Z.","year":"2016","unstructured":"Carter B.Z.; Mak P.Y.; Mu H.; Zhou H.; Mak D.H.; Schober W.; Leverson J.D.; Zhang B.; Bhatia R.; Huang X.; Cortes J.; Kantarjian H.; Konopleva M.; Andreeff M.; Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med 2016,8(355)","journal-title":"Sci Transl Med"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/1541-4337.12136","volume":"14","author":"Hamed I.","year":"2015","unstructured":"Hamed I.; \u00d6zogul F.; \u00d6zogul Y.; Regenstein J.M.; Marine bioactive compounds and their health benefits: A review. Compr Rev Food Sci Food Saf 2015,14(4),446-465","journal-title":"Compr Rev Food Sci Food Saf"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jep.2012.05.046","volume":"142","author":"Liu L.","year":"2012","unstructured":"Liu L.; Heinrich M.; Myers S.; Dworjanyn S.A.; Towards a better understanding of medicinal uses of the brown seaweed Sargassum in Traditional Chinese Medicine: A phytochemical and pharma-cological review. J Ethnopharmacol 2012,142(3),591-619","journal-title":"J Ethnopharmacol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1126\/science.286.5439.531","volume":"286","author":"Golub T.R.","year":"1999","unstructured":"Golub T.R.; Slonim D.K.; Tamayo P.; Huard C.; Gaasenbeek M.; Mesirov J.P.; Coller H.; Loh M.L.; Downing J.R.; Caligiuri M.A.; Bloomfield C.D.; Lander E.S.; Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999,286(5439),531-537","journal-title":"Science"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.biomaterials.2009.09.080","volume":"31","author":"Xiong X.B.","year":"2010","unstructured":"Xiong X.B.; Ma Z.; Lai R.; Lavasanifar A.; The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials 2010,31(4),757-768","journal-title":"Biomaterials"},{"key":"ref=13","first-page":"437","volume":"5","author":"Ghosh D.","year":"2014","unstructured":"Ghosh D.; Dey S.K.; Saha C.; Protective effect of black tea extract during chemotherapeutic drug induced oxidative damage on normal lymphocytes in comparison with cancerous K562 cells. Int J Sci Eng Res 2014,5(2),437-447","journal-title":"Int J Sci Eng Res"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","volume":"13","author":"Greuber E.K.","year":"2013","unstructured":"Greuber E.K.; Smith-Pearson P.; Wang J.; Pendergast A.M.; Role of ABL family kinases in cancer: From leukaemia to solid tumours. Nat Rev Cancer 2013,13(8),559-571","journal-title":"Nat Rev Cancer"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"Deininger M.W.","year":"2000","unstructured":"Deininger M.W.; Goldman J.M.; Melo J.V.; The molecular biology of chronic myeloid leukemia. Blood 2000,96(10),3343-3356","journal-title":"Blood"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.6004\/jnccn.2012.0009","volume":"10","author":"O\u2019Brien S.","year":"2012","unstructured":"O\u2019Brien S.; Abboud C.N.; Akhtari M.; Altman J.; Berman E.; DeAngelo D.J.; Devine S.; Fathi A.T.; Gotlib J.; Jagasia M.; Moore J.O.; Pinilla-Ibarz J.; Radich J.P.; Reddy V.V.; Shah N.P.; Shami P.J.; Smith B.D.; Snyder D.S.; Wetzler M.; Yunus F.; Chronic myelogenous leukemia. J Natl Compr Canc Netw 2012,10,64-110","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/bph.12183","volume":"169","author":"Sinclair A.","year":"2013","unstructured":"Sinclair A.; Latif A.L.; Holyoake T.L.; Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol 2013,169(8),1693-1707","journal-title":"Br J Pharmacol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/nar\/29.7.1534","volume":"29","author":"Collis S.J.","year":"2001","unstructured":"Collis S.J.; Tighe A.; Scott S.D.; Roberts S.A.; Hendry J.H.; Margison G.P.; Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 2001,29(7),1534-1538","journal-title":"Nucleic Acids Res"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V86.3.1148.1148","volume":"86","author":"Bedi A.","year":"1995","unstructured":"Bedi A.; Barber J.P.; Bedi G.C.; el-Deiry W.S.; Sidransky D.; Vala M.S.; Akhtar A.J.; Hilton J.; Jones R.J.; BCR-ABL-mediated inhibition of apoptosis with delay of G2\/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995,86(3),1148-1158","journal-title":"Blood"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.1038\/sj.onc.1206087","volume":"21","author":"Skorski T.","year":"2002","unstructured":"Skorski T.; BCR\/ABL regulates response to DNA damage: The role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002,21(56),8591-8604","journal-title":"Oncogene"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10555-012-9405-5","volume":"32","author":"Cook G.J.","year":"2013","unstructured":"Cook G.J.; Pardee T.S.; Animal models of leukemia: Any closer to the real thing? Cancer Metastasis Rev 2013,32(1-2),63-76","journal-title":"Cancer Metastasis Rev"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","volume":"16","author":"Shet A.S.","year":"2002","unstructured":"Shet A.S.; Jahagirdar B.N.; Verfaillie C.M.; Chronic myelogenous leukemia: Mechanisms underlying disease progression. Leukemia 2002,16(8),1402-1411","journal-title":"Leukemia"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"Mahon F.X.","year":"2000","unstructured":"Mahon F.X.; Deininger M.W.; Schultheis B.; Chabrol J.; Reiffers J.; Goldman J.M.; Melo J.V.; Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood 2000,96(3),1070-1079","journal-title":"Blood"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"Druker B.J.","year":"1996","unstructured":"Druker B.J.; Tamura S.; Buchdunger E.; Ohno S.; Segal G.M.; Fanning S.; Zimmermann J.; Lydon N.B.; Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996,2(5),561-566","journal-title":"Nat Med"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"Druker B.J.","year":"2006","unstructured":"Druker B.J.; Guilhot F.; O\u2019Brien S.G.; Gathmann I.; Kantarjian H.; Gattermann N.; Deininger M.W.; Silver R.T.; Goldman J.M.; Stone R.M.; Cervantes F.; Hochhaus A.; Powell B.L.; Gabrilove J.L.; Rousselot P.; Reiffers J.; Cornelissen J.J.; Hughes T.; Agis H.; Fischer T.; Verhoef G.; Shepherd J.; Saglio G.; Gratwohl A.; Nielsen J.L.; Radich J.P.; Simonsson B.; Taylor K.; Baccarani M.; So C.; Letvak L.; Larson R.A.; Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006,355(23),2408-2417","journal-title":"N Engl J Med"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","volume":"4","author":"Bhamidipati P.K.","year":"2013","unstructured":"Bhamidipati P.K.; Kantarjian H.; Cortes J.; Cornelison A.M.; Jabbour E.; Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol 2013,4(2),103-117","journal-title":"Ther Adv Hematol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"Thomas J.","year":"2004","unstructured":"Thomas J.; Wang L.; Clark R.E.; Pirmohamed M.; Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 2004,104(12),3739-3745","journal-title":"Blood"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","volume":"92","author":"Gambacorti-Passerini C.","year":"2000","unstructured":"Gambacorti-Passerini C.; Barni R.; le Coutre P.; Zucchetti M.; Cabrita G.; Cleris L.; Rossi F.; Gianazza E.; Brueggen J.; Cozens R.; Pioltelli P.; Pogliani E.; Corneo G.; Formelli F.; D\u2019Incalci M.; Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000,92(20),1641-1650","journal-title":"J Natl Cancer Inst"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.leu.2404197","volume":"20","author":"Villuendas R.","year":"2006","unstructured":"Villuendas R.; Steegmann J.L.; Pollan M.; Tracey L.; Granda A.; Fernandez-Ruiz E.; Casado L.F.; Martinez J.; Martinez P.; Lombardia L.; Villalon L.; Odriozola J.; Piris M.A.; Identification of genes involved in imatinib resistance in CML: A gene-expression profiling approach. Leukemia 2006,20(6),1047-1054","journal-title":"Leukemia"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1750-9378-8-23","volume":"8","author":"Mughal A.","year":"2013","unstructured":"Mughal A.; Aslam H.M.; Khan A.M.; Saleem S.; Umah R.; Saleem M.; Bcr-Abl tyrosine kinase inhibitors- current status. Infect Agent Cancer 2013,8,23","journal-title":"Infect Agent Cancer"},{"key":"ref=31","first-page":"243","volume":"8","author":"Miller G.D.","year":"2014","unstructured":"Miller G.D.; Bruno B.J.; Lim C.S.; Resistant mutations in CML and Ph(+)ALL - role of ponatinib. Biologics 2014,8,243-254","journal-title":"Biologics"},{"key":"ref=32","volume":"4","author":"Hu Z.","year":"2009","unstructured":"Hu Z.; Pan X.F.; Wu F.Q.; Ma L.Y.; Liu D.P.; Liu Y.; Feng T.T.; Meng F.Y.; Liu X.L.; Jiang Q.L.; Chen X.Q.; Liu J.L.; Liu P.; Chen Z.; Chen S.J.; Zhou G.B.; Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS One 2009,4(7)","journal-title":"PLoS One"},{"key":"ref=33","unstructured":"FDA, U.S. Food and Drug Administration\n                     https:\/\/www.accessdata. fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.biocel.2005.03.004","volume":"37","author":"Tolomeo M.","year":"2005","unstructured":"Tolomeo M.; Grimaudo S.; Di Cristina A.; Roberti M.; Pizzirani D.; Meli M.; Dusonchet L.; Gebbia N.; Abbadessa V.; Crosta L.; Barucchello R.; Grisolia G.; Invidiata F.; Simoni D.; Pterostilbene and 3\u2032-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. Int J Biochem Cell Biol 2005,37(8),1709-1726","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/leu.2008.74","volume":"22","author":"Zhang H.","year":"2008","unstructured":"Zhang H.; Trachootham D.; Lu W.; Carew J.; Giles F.J.; Keating M.J.; Arlinghaus R.B.; Huang P.; Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 2008,22(6),1191-1199","journal-title":"Leukemia"},{"key":"ref=36","first-page":"4909","volume":"34","author":"Eucker J.","year":"2014","unstructured":"Eucker J.; Zang C.; Zhou Y.; Li X.; Habbel P.; Neumann C.; Scholz C.; Liu H.; The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro. Anticancer Res 2014,34(9),4909-4914","journal-title":"Anticancer Res"},{"key":"ref=37","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/137414","volume":"2013","author":"Yardley D.A.","year":"2013","unstructured":"Yardley D.A.; Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer 2013,2013","journal-title":"Int J Breast Cancer"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"Mokhtari R.B.","year":"2017","unstructured":"Mokhtari R.B.; Homayouni T.S.; Baluch N.; Morgatskaya E.; Kumar S.; Das B.; Yeger H.; Combination therapy in combating cancer. Oncotarget 2017,8(23),38022-38043","journal-title":"Oncotarget"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","volume":"101","author":"Nimmanapalli R.","year":"2003","unstructured":"Nimmanapalli R.; Fuino L.; Stobaugh C.; Richon V.; Bhalla K.; Cotreatment with the histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003,101(8),3236-3239","journal-title":"Blood"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4161\/cbt.28931","volume":"15","author":"Bu Q.","year":"2014","unstructured":"Bu Q.; Cui L.; Li J.; Du X.; Zou W.; Ding K.; Pan J.; SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer Biol Ther 2014,15(7),951-962","journal-title":"Cancer Biol Ther"},{"key":"ref=41","volume":"11","author":"Lin T.Y.","year":"2016","unstructured":"Lin T.Y.; Chen K.C.; Liu H.J.; Liu A.J.; Wang K.L.; Shih C.M.; MicroRNA-1301-Mediated RanGAP1 downregulation induces bcr-abl nuclear entrapment to enhance imatinib efficacy in chronic myeloid leukemia cells. PLoS One 2016,11(5)","journal-title":"PLoS One"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jphs.2015.10.008","volume":"129","author":"Wei Y.","year":"2015","unstructured":"Wei Y.; To K.K.; Au-Yeung S.C.; Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells. J Pharmacol Sci 2015,129(4),210-215","journal-title":"J Pharmacol Sci"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/leu.2013.323","volume":"28","author":"Zhang M.","year":"2014","unstructured":"Zhang M.; Luo Z.; Liu H.; Croce C.M.; Burke T.R.; Bottaro D.P.; Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist. Leukemia 2014,28(4),948-951","journal-title":"Leukemia"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/sj.leu.2402775","volume":"16","author":"Tipping A.J.","year":"2002","unstructured":"Tipping A.J.; Mahon F.X.; Zafirides G.; Lagarde V.; Goldman J.M.; Melo J.V.; Drug responses of imatinib mesylate-resistant cells: Synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002,16(12),2349-2357","journal-title":"Leukemia"},{"key":"ref=45","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2014.3","volume":"3","author":"Crawford L.J.","year":"2014","unstructured":"Crawford L.J.; Chan E.T.; Aujay M.; Holyoake T.L.; Melo J.V.; Jorgensen H.G.; Suresh S.; Walker B.; Irvine A.E.; Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models. Oncogenesis 2014,3","journal-title":"Oncogenesis"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","volume":"124","author":"Gallipoli P.","year":"2014","unstructured":"Gallipoli P.; Cook A.; Rhodes S.; Hopcroft L.; Wheadon H.; Whetton A.D.; Jorgensen H.G.; Bhatia R.; Holyoake T.L.; JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood 2014,124(9),1492-1501","journal-title":"Blood"},{"key":"ref=47","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/214186","volume":"2010","author":"Sithranga Boopathy N.","year":"2010","unstructured":"Sithranga Boopathy N.; Kathiresan K.; Anticancer drugs from marine flora: an overview. J Oncol 2010,2010","journal-title":"J Oncol"},{"key":"ref=48","first-page":"1","volume":"6","author":"Kolanjinathan K.","year":"2014","unstructured":"Kolanjinathan K.; Ganesh P.; Saranraj P.; Pharmacological importance of seaweeds: A review. World J Fish Marine Sci 2014,6,1-15","journal-title":"World J Fish Marine Sci"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4490\/algae.2010.25.4.155","volume":"25","author":"Cornish M.L.","year":"2010","unstructured":"Cornish M.L.; Garbary D.J.; Antioxidants from macroalgae: Potential applications in human health and nutrition. Algae 2010,25(4),155-171","journal-title":"Algae"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/jpy.12326","volume":"51","author":"Hafting J.T.","year":"2015","unstructured":"Hafting J.T.; Craigie J.S.; Stengel D.B.; Loureiro R.R.; Buschmann A.H.; Yarish C.; Edwards M.D.; Critchley A.T.; Prospects and challenges for industrial production of seaweed bioactives. J Phycol 2015,51(5),821-837","journal-title":"J Phycol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2684-8_1","volume":"1308","author":"Stengel D.B.","year":"2015","unstructured":"Stengel D.B.; Connan S.; Marine algae: A source of biomass for biotechnological applications. Methods Mol Biol 2015,1308,1-37","journal-title":"Methods Mol Biol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00217-008-0918-7","volume":"228","author":"Heo S-J.","year":"2008","unstructured":"Heo S-J.; Ko S-C.; Kang S-M.; Kang H-S.; Kim J-P.; Kim S-H.; Lee K-W.; Cho M-G.; Jeon Y-J.; Cytoprotective effect of fucoxanthin isolated from brown algae Sargassum siliquastrum against HO-induced cell damage. Eur Food Res Technol 2008,228,145-151","journal-title":"Eur Food Res Technol"},{"key":"ref=53","author":"Fleurence J.","year":"2016","unstructured":"Fleurence J.; Levine I.;  Seaweed in health and disease prevention 2016","journal-title":"Seaweed in health and disease prevention"},{"key":"ref=54","first-page":"8","volume":"3","author":"Sharif N.","year":"2014","unstructured":"Sharif N.; Munir N.; Saleem F.; Aslam F.; Naz S.; Prolific anticancer bioactivity of algal extracts. Cell 2014,3(4),8","journal-title":"Cell"},{"key":"ref=55","first-page":"M4","author":"Chojnacka K.","year":"2012","unstructured":"Chojnacka K.; Saeid A.; Witkowska Z.; Tuhy L.; In Biologically active compounds in seaweed extracts\u2014the prospects for the application. Open Conf Proc J 2012,M4","journal-title":"Open Conf Proc J"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.plipres.2007.07.001","volume":"46","author":"Dembitsky V.M.","year":"2007","unstructured":"Dembitsky V.M.; Maoka T.; Allenic and cumulenic lipids. Prog Lipid Res 2007,46(6),328-375","journal-title":"Prog Lipid Res"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/md9020278","volume":"9","author":"Maoka T.","year":"2011","unstructured":"Maoka T.; Carotenoids in marine animals. Mar Drugs 2011,9(2),278-293","journal-title":"Mar Drugs"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3390\/md9061101","volume":"9","author":"Takaichi S.","year":"2011","unstructured":"Takaichi S.; Carotenoids in algae: Distributions, biosyntheses and functions. Mar Drugs 2011,9(6),1101-1118","journal-title":"Mar Drugs"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3390\/nu6031293","volume":"6","author":"Barros M.P.","year":"2014","unstructured":"Barros M.P.; Poppe S.C.; Bondan E.F.; Neuroprotective properties of the marine carotenoid astaxanthin and omega-3 fatty acids, and perspectives for the natural combination of both in krill oil. Nutrients 2014,6(3),1293-1317","journal-title":"Nutrients"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.foodres.2015.07.047","volume":"76","author":"Saini R.K.","year":"2015","unstructured":"Saini R.K.; Nile S.H.; Park S.W.; Carotenoids from fruits and vegetables: Chemistry, analysis, occurrence, bioavailability and biological activities. Food Res Int 2015,76(Pt 3),735-750","journal-title":"Food Res Int"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.foodres.2011.06.007","volume":"46","author":"Fern\u00e1ndez-Garc\u00eda E.","year":"2012","unstructured":"Fern\u00e1ndez-Garc\u00eda E.; Carvajal-L\u00e9rida I.; Jar\u00e9n-Gal\u00e1n M.; Garrido-Fern\u00e1ndez J.; P\u00e9rez-G\u00e1lvez A.; Hornero-M\u00e9ndez D.; Carotenoids bioavailability from foods: From plant pigments to efficient biological activities. Food Res Int 2012,46(2),438-450","journal-title":"Food Res Int"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/ijc.23860","volume":"123","author":"Ishikawa C.","year":"2008","unstructured":"Ishikawa C.; Tafuku S.; Kadekaru T.; Sawada S.; Tomita M.; Okudaira T.; Nakazato T.; Toda T.; Uchihara J.N.; Taira N.; Ohshiro K.; Yasumoto T.; Ohta T.; Mori N.; Anti-adult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. Int J Cancer 2008,123(11),2702-2712","journal-title":"Int J Cancer"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.3390\/molecules17033202","volume":"17","author":"Tanaka T.","year":"2012","unstructured":"Tanaka T.; Shnimizu M.; Moriwaki H.; Cancer chemoprevention by carotenoids. Molecules 2012,17(3),3202-3242","journal-title":"Molecules"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1021\/jf071848a","volume":"55","author":"Sachindra N.M.","year":"2007","unstructured":"Sachindra N.M.; Sato E.; Maeda H.; Hosokawa M.; Niwano Y.; Kohno M.; Miyashita K.; Radical scavenging and singlet oxygen quenching activity of marine carotenoid fucoxanthin and its metabolites. J Agric Food Chem 2007,55(21),8516-8522","journal-title":"J Agric Food Chem"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.3390\/nu5124978","volume":"5","author":"Rengarajan T.","year":"2013","unstructured":"Rengarajan T.; Rajendran P.; Nandakumar N.; Balasubramanian M.P.; Nishigaki I.; Cancer preventive efficacy of marine carotenoid fucoxanthin: Cell cycle arrest and apoptosis. Nutrients 2013,5(12),4978-4989","journal-title":"Nutrients"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3390\/md9101806","volume":"9","author":"Peng J.","year":"2011","unstructured":"Peng J.; Yuan J-P.; Wu C-F.; Wang J-H.; Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: Metabolism and bioactivities relevant to human health. Mar Drugs 2011,9(10),1806-1828","journal-title":"Mar Drugs"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s11095-008-9661-9","volume":"25","author":"Anand P.","year":"2008","unstructured":"Anand P.; Kunnumakkara A.B.; Sundaram C.; Harikumar K.B.; Tharakan S.T.; Lai O.S.; Sung B.; Aggarwal B.B.; Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 2008,25(9),2097-2116","journal-title":"Pharm Res"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3390\/md10092055","volume":"10","author":"Wang J.","year":"2012","unstructured":"Wang J.; Chen S.; Xu S.; Yu X.; Ma D.; Hu X.; Cao X.; \n                        In vivo induction of apoptosis by fucoxanthin, a marine carotenoid, associated with down-regulating STAT3\/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice. Mar Drugs 2012,10(9),2055-2068","journal-title":"Mar Drugs"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.etap.2018.02.006","volume":"59","author":"Almeida T.P.","year":"2018","unstructured":"Almeida T.P.; Ferreira J.; Vettorazzi A.; Azqueta A.; Rocha E.; Ramos A.A.; Cytotoxic activity of fucoxanthin, alone and in combination with the cancer drugs imatinib and doxorubicin, in CML cell lines. Environ Toxicol Pharmacol 2018,59,24-33","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","volume":"107","author":"Carter B.Z.","year":"2006","unstructured":"Carter B.Z.; Mak D.H.; Schober W.D.; Cabreira-Hansen M.; Beran M.; McQueen T.; Chen W.; Andreeff M.; Regulation of survivin expression through Bcr-Abl\/MAPK cascade: Targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 2006,107(4),1555-1563","journal-title":"Blood"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI11991","volume":"107","author":"Baldwin A.S.","year":"2001","unstructured":"Baldwin A.S.; Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001,107(3),241-246","journal-title":"J Clin Invest"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"66287","DOI":"10.18632\/oncotarget.11507","volume":"7","author":"Carr\u00e0 G.","year":"2016","unstructured":"Carr\u00e0 G.; Torti D.; Crivellaro S.; Panuzzo C.; Taulli R.; Cilloni D.; Guerrasio A.; Saglio G.; Morotti A.; The BCR-ABL\/NF-\u03baB signal transduction network: A long lasting relationship in Philadelphia positive Leukemias. Oncotarget 2016,7(40),66287-66298","journal-title":"Oncotarget"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cbpc.2005.10.005","volume":"142","author":"Konishi I.","year":"2006","unstructured":"Konishi I.; Hosokawa M.; Sashima T.; Kobayashi H.; Miyashita K.; Halocynthiaxanthin and fucoxanthinol isolated from Halocynthia roretzi induce apoptosis in human leukemia, breast and colon cancer cells. Comp Biochem Physiol C Toxicol Pharmacol 2006,142(1-2),53-59","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3136\/fstr.5.243","volume":"5","author":"Hosokawa M.","year":"1999","unstructured":"Hosokawa M.; Wanezaki S.; Miyauchi K.; Kurihara H.; Kohno H.; Kawabata J.; Odashima S.; Takahashi K.; Apoptosis-inducing effect of fucoxanthin on human leukemia cell line HL-60. Food Sci Technol Res 1999,5(3),243-246","journal-title":"Food Sci Technol Res"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jff.2008.09.015","volume":"1","author":"Nakazawa Y.","year":"2009","unstructured":"Nakazawa Y.; Sashima T.; Hosokawa M.; Miyashita K.; Comparative evaluation of growth inhibitory effect of stereoisomers of fucoxanthin in human cancer cell lines. J Funct Foods 2009,1(1),88-97","journal-title":"J Funct Foods"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.tiv.2010.05.023","volume":"24","author":"Kim K-N.","year":"2010","unstructured":"Kim K-N.; Heo S-J.; Kang S-M.; Ahn G.; Jeon Y-J.; Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. Toxicol In Vitro 2010,24(6),1648-1654","journal-title":"Toxicol In Vitro"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1271\/bbb.69.224","volume":"69","author":"Kotake-Nara E.","year":"2005","unstructured":"Kotake-Nara E.; Terasaki M.; Nagao A.; Characterization of apoptosis induced by fucoxanthin in human promyelocytic leukemia cells. Biosci Biotechnol Biochem 2005,69(1),224-227","journal-title":"Biosci Biotechnol Biochem"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bbagen.2011.02.008","volume":"1810","author":"Ganesan P.","year":"2011","unstructured":"Ganesan P.; Noda K.; Manabe Y.; Ohkubo T.; Tanaka Y.; Maoka T.; Sugawara T.; Hirata T.; Siphonaxanthin, a marine carotenoid from green algae, effectively induces apoptosis in human leukemia (HL-60) cells. Biochim Biophys Acta 2011,1810(5),497-503","journal-title":"Biochim Biophys Acta"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"9805","DOI":"10.1021\/jf062204q","volume":"54","author":"Sugawara T.","year":"2006","unstructured":"Sugawara T.; Matsubara K.; Akagi R.; Mori M.; Hirata T.; Antiangiogenic activity of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. J Agric Food Chem 2006,54(26),9805-9810","journal-title":"J Agric Food Chem"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.phymed.2010.05.005","volume":"17","author":"Ganesan P.","year":"2010","unstructured":"Ganesan P.; Matsubara K.; Ohkubo T.; Tanaka Y.; Noda K.; Sugawara T.; Hirata T.; Anti-angiogenic effect of siphonaxanthin from green alga, Codium fragile. Phytomedicine 2010,17(14),1140-1144","journal-title":"Phytomedicine"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"261","DOI":"10.18632\/oncotarget.461","volume":"3","author":"Vicente-Due\u00f1as C.","year":"2012","unstructured":"Vicente-Due\u00f1as C.; Barajas-Diego M.; Romero-Camarero I.; Gonz\u00e1lez-Herrero I.; Flores T.; S\u00e1nchez-Garc\u00eda I.; Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice. Oncotarget 2012,3(3),261-266","journal-title":"Oncotarget"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-014-0061-9","volume":"7","author":"Wang L.","year":"2014","unstructured":"Wang L.; Xiao H.; Zhang X.; Wang C.; Huang H.; The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. J Hematol Oncol 2014,7(1),61","journal-title":"J Hematol Oncol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.4103\/0973-1296.127368","volume":"10","author":"Gharib A.","year":"2014","unstructured":"Gharib A.; Faezizadeh Z.; \n                        In vitro anti-telomerase activity of novel lycopene-loaded nanospheres in the human leukemia cell line K562. Pharmacogn Mag 2014,10(Suppl. 1),S157-S163","journal-title":"Pharmacogn Mag"},{"key":"ref=84","first-page":"118","volume":"19","author":"Faezizadeh Z.","year":"2015","unstructured":"Faezizadeh Z.; Gharib A.; Godarzi M.; The effect of \u03b2-ionone on telomerase activity in the human leukemia cell line K562. J Kermanshah Uni Med Sci 2015,19(3),118-127","journal-title":"J Kermanshah Uni Med Sci"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4314\/tjpr.v14i2.1","volume":"14","author":"Gharib A.","year":"2015","unstructured":"Gharib A.; Faezizadeh Z.; Godarzee M.; Preparation and characterization of nanoliposomal beta-cryptoxanthin and its effect on proliferation and apoptosis in human leukemia cell line K562. Trop J Pharm Res 2015,14(2),187-194","journal-title":"Trop J Pharm Res"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.abb.2011.05.004","volume":"512","author":"Zhang X.","year":"2011","unstructured":"Zhang X.; Zhao W.E.; Hu L.; Zhao L.; Huang J.; Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARgamma) in K562 cancer cells. Arch Biochem Biophys 2011,512(1),96-106","journal-title":"Arch Biochem Biophys"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3324\/haematol.2016.153270","volume":"102","author":"Wang J.","year":"2017","unstructured":"Wang J.; Lu L.; Kok C.H.; Saunders V.A.; Goyne J.M.; Dang P.; Leclercq T.M.; Hughes T.P.; White D.L.; Increased peroxisome proliferator-activated receptor \u03b3 activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica 2017,102(5),843-853","journal-title":"Haematologica"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"Prost S.","year":"2015","unstructured":"Prost S.; Relouzat F.; Spentchian M.; Ouzegdouh Y.; Saliba J.; Massonnet G.; Beressi J.P.; Verhoeyen E.; Raggueneau V.; Maneglier B.; Castaigne S.; Chomienne C.; Chretien S.; Rousselot P.; Leboulch P.; Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature 2015,525(7569),380-383","journal-title":"Nature"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbagen.2005.09.007","volume":"1726","author":"Das S.K.","year":"2005","unstructured":"Das S.K.; Hashimoto T.; Shimizu K.; Yoshida T.; Sakai T.; Sowa Y.; Komoto A.; Kanazawa K.; Fucoxanthin induces cell cycle arrest at G 0\/G 1 phase in human colon carcinoma cells through up-regulation of p21 WAF1\/Cip1. Biochim Biophys Acta 2005,1726(3),328-335","journal-title":"Biochim Biophys Acta"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/ijc.22111","volume":"119","author":"Lian F.","year":"2006","unstructured":"Lian F.; Hu K.Q.; Russell R.M.; Wang X.D.; \u03b2-Cryptoxanthin suppresses the growth of immortalized human bronchial epithelial cells and non-small-cell lung cancer cells and up-regulates retinoic acid receptor \u03b2 expression. Int J Cancer 2006,119(9),2084-2089","journal-title":"Int J Cancer"},{"key":"ref=91","first-page":"2290","volume":"267","author":"Stivala L.A.","year":"2000","unstructured":"Stivala L.A.; Savio M.; Quarta S.; Scotti C.; Cazzalini O.; Rossi L.; Scovassi I.A.; Pizzala R.; Melli R.; Bianchi L.; The antiproliferative effect of \u03b2-carotene requires p21waf1\/cip1 in normal human fibroblasts. FEBS J 2000,267(8),2290-2296","journal-title":"FEBS J"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1080\/10428190400003317","volume":"45","author":"Liu J-H.","year":"2004","unstructured":"Liu J-H.; Yen C-C.; Lin Y-C.; Gau J-P.; Yang M-H.; Chao T-C.; Hsiao L-T.; Wang W-S.; Tsai Y-C.; Chen P-M.; Overexpression of cyclin D1 in accelerated-phase chronic myeloid leukemia. Leuk Lymphoma 2004,45(12),2419-2425","journal-title":"Leuk Lymphoma"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1177\/0960327116630352","volume":"35","author":"Santos G.","year":"2016","unstructured":"Santos G.; Almeida M.; Antunes L.; Bianchi M.; Effect of bixin on DNA damage and cell death induced by doxorubicin in HL60 cell line. Hum Exp Toxicol 2016,35(12),1319-1327","journal-title":"Hum Exp Toxicol"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/jn\/133.2.381","volume":"133","author":"Palozza P.","year":"2003","unstructured":"Palozza P.; Serini S.; Torsello A.; Di Nicuolo F.; Piccioni E.; Ubaldi V.; Pioli C.; Wolf F.I.; Calviello G.; Beta-carotene regulates NF-kappaB DNA-binding activity by a redox mechanism in human leukemia and colon adenocarcinoma cells. J Nutr 2003,133(2),381-388","journal-title":"J Nutr"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbadis.2004.12.005","volume":"1740","author":"Sacha T.","year":"2005","unstructured":"Sacha T.; Zawada M.; Hartwich J.; Lach Z.; Polus A.; Szostek M.; Zdzi Owska E.; Libura M.; Bodzioch M.; Dembinska-Kiec A.; Skotnicki A.B.; Goralczyk R.; Wertz K.; Riss G.; Moele C.; Langmann T.; Schmitz G.; The effect of beta-carotene and its derivatives on cytotoxicity, differentiation, proliferative potential and apoptosis on the three human acute leukemia cell lines: U-937, HL-60 and TF-1. Biochim Biophys Acta 2005,1740(2),206-214","journal-title":"Biochim Biophys Acta"},{"key":"ref=96","first-page":"1009","volume":"40","author":"Upadhyaya K.R.","year":"2007","unstructured":"Upadhyaya K.R.; Radha K.S.; Madhyastha H.K.; Cell cycle regulation and induction of apoptosis by beta-carotene in U937 and HL-60 leukemia cells. J Biochem Mol Biol 2007,40(6),1009-1015","journal-title":"J Biochem Mol Biol"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00343-010-9054-x","volume":"28","author":"Yang H.","year":"2010","unstructured":"Yang H.; Zeng M.; Dong S.; Liu Z.; Li R.; Anti-proliferative activity of phlorotannin extracts from brown algae Laminaria japonica Aresch. Chin J Oceanology Limnol 2010,28(1),122-130","journal-title":"Chin J Oceanology Limnol"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cbi.2011.02.026","volume":"190","author":"Liu J.Y.","year":"2011","unstructured":"Liu J.Y.; Liu Z.; Wang D.M.; Li M.M.; Wang S.X.; Wang R.; Chen J.P.; Wang Y.F.; Yang D.P.; Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway. Chem Biol Interact 2011,190(2-3),91-101","journal-title":"Chem Biol Interact"},{"key":"ref=99","volume":"6","author":"Merhi F.","year":"2011","unstructured":"Merhi F.; Tang R.; Piedfer M.; Mathieu J.; Bombarda I.; Zaher M.; Kolb J-P.; Billard C.; Bauvois B.; Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells. PLoS One 2011,6(10)","journal-title":"PLoS One"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.leu.2404098","volume":"20","author":"Quiney C.","year":"2006","unstructured":"Quiney C.; Billard C.; Faussat A.M.; Salanoubat C.; Ensaf A.; Nait-Si Y.; Fourneron J.D.; Kolb J.P.; Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Leukemia 2006,20(3),491-497","journal-title":"Leukemia"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/sj.leu.2404134","volume":"20","author":"Quiney C.","year":"2006","unstructured":"Quiney C.; Billard C.; Mirshahi P.; Fourneron J.; Kolb J.; Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells. Leukemia 2006,20(4),583","journal-title":"Leukemia"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1007\/s10495-015-1170-9","volume":"20","author":"Wiechmann K.","year":"2015","unstructured":"Wiechmann K.; M\u00fcller H.; Fischer D.; Jauch J.; Werz O.; The acylphloroglucinols hyperforin and myrtucommulone A cause mitochondrial dysfunctions in leukemic cells by direct interference with mitochondria. Apoptosis 2015,20(11),1508-1517","journal-title":"Apoptosis"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.3390\/md12094934","volume":"12","author":"Barbosa M.","year":"2014","unstructured":"Barbosa M.; Valent\u00e3o P.; Andrade P.B.; Bioactive compounds from macroalgae in the new millennium: Implications for neurodegenerative diseases. Mar Drugs 2014,12(9),4934-4972","journal-title":"Mar Drugs"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3390\/ijms18061327","volume":"18","author":"Catarino M.D.","year":"2017","unstructured":"Catarino M.D.; Silva A.M.S.; Cardoso S.M.; Fucaceae: A source of bioactive phlorotannins. Int J Mol Sci 2017,18(6),1327","journal-title":"Int J Mol Sci"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.etap.2011.09.004","volume":"32","author":"Thomas N.V.","year":"2011","unstructured":"Thomas N.V.; Kim S-K.; Potential pharmacological applications of polyphenolic derivatives from marine brown algae. Environ Toxicol Pharmacol 2011,32(3),325-335","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1017\/S0007114516000210","volume":"115","author":"Corona G.","year":"2016","unstructured":"Corona G.; Ji Y.; Anegboonlap P.; Hotchkiss S.; Gill C.; Yaqoob P.; Spencer J.P.; Rowland I.; Gastrointestinal modifications and bioavailability of brown seaweed phlorotannins and effects on inflammatory markers. Br J Nutr 2016,115(7),1240-1253","journal-title":"Br J Nutr"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.phytol.2015.09.007","volume":"14","author":"P\u00e1dua D.","year":"2015","unstructured":"P\u00e1dua D.; Rocha E.; Gargiulo D.; Ramos A.; Bioactive compounds from brown seaweeds: Phloroglucinol, fucoxanthin and fucoidan as promising therapeutic agents against breast cancer. Phytochem Lett 2015,14,91-98","journal-title":"Phytochem Lett"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1369\/0022155412468426","volume":"61","author":"Ha D.","year":"2013","unstructured":"Ha D.; Bing S.J.; Cho J.; Ahn G.; Kim D.S.; Al-Amin M.; Park S.J.; Jee Y.; Phloroglucinol protects small intestines of mice from ionizing radiation by regulating apoptosis-related molecules: A comparative immunohistochemical study. J Histochem Cytochem 2013,61(1),63-74","journal-title":"J Histochem Cytochem"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cbi.2010.02.031","volume":"185","author":"Kang K.A.","year":"2010","unstructured":"Kang K.A.; Zhang R.; Chae S.; Lee S.J.; Kim J.; Kim J.; Jeong J.; Lee J.; Shin T.; Lee N.H.; Phloroglucinol (1, 3, 5-trihydroxybenzene) protects against ionizing radiation-induced cell damage through inhibition of oxidative stress in vitro and in vivo. Chem Biol Interact 2010,185(3),215-226","journal-title":"Chem Biol Interact"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ptr.2298","volume":"22","author":"Moon C.","year":"2008","unstructured":"Moon C.; Kim S.H.; Kim J.C.; Hyun J.W.; Lee N.H.; Park J.W.; Shin T.; Protective effect of phlorotannin components phloroglucinol and eckol on radiation-induced intestinal injury in mice. Phytother Res 2008,22(2),238-242","journal-title":"Phytother Res"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/BF02980106","volume":"27","author":"Kang H.S.","year":"2004","unstructured":"Kang H.S.; Chung H.Y.; Kim J.Y.; Son B.W.; Jung H.A.; Choi J.S.; Inhibitory phlorotannins from the edible brown alga Ecklonia stolonifera on total reactive oxygen species (ROS) generation. Arch Pharm Res 2004,27(2),194-198","journal-title":"Arch Pharm Res"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1021\/jf801133h","volume":"56","author":"Zou Y.","year":"2008","unstructured":"Zou Y.; Qian Z-J.; Li Y.; Kim M-M.; Lee S-H.; Kim S-K.; Antioxidant effects of phlorotannins isolated from Ishige okamurae in free radical mediated oxidative systems. J Agric Food Chem 2008,56(16),7001-7009","journal-title":"J Agric Food Chem"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.foodchem.2010.11.111","volume":"126","author":"Nwosu F.","year":"2011","unstructured":"Nwosu F.; Morris J.; Lund V.A.; Stewart D.; Ross H.A.; McDougall G.J.; Anti-proliferative and potential anti-diabetic effects of phenolic-rich extracts from edible marine algae. Food Chem 2011,126(3),1006-1012","journal-title":"Food Chem"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11418-012-0709-0","volume":"67","author":"Yoon J.S.","year":"2013","unstructured":"Yoon J.S.; Kasin Yadunandam A.; Kim S.J.; Woo H.C.; Kim H.R.; Kim G.D.; Dieckol, isolated from Ecklonia stolonifera, induces apoptosis in human hepatocellular carcinoma Hep3B cells. J Nat Med 2013,67(3),519-527","journal-title":"J Nat Med"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00432-014-1819-8","volume":"141","author":"Ahn J.H.","year":"2015","unstructured":"Ahn J.H.; Yang Y.I.; Lee K.T.; Choi J.H.; Dieckol, isolated from the edible brown algae Ecklonia cava, induces apoptosis of ovarian cancer cells and inhibits tumor xenograft growth. J Cancer Res Clin Oncol 2015,141(2),255-268","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0939-6411(03)00046-8","volume":"56","author":"Hostanska K.","year":"2003","unstructured":"Hostanska K.; Reichling J.; Bommer S.; Weber M.; Saller R.; Hyperforin a constituent of St John\u2019s wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur J Pharm Biopharm 2003,56(1),121-132","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=117","first-page":"269","volume":"40","author":"Zaher M.","year":"2012","unstructured":"Zaher M.; Tang R.; Bombarda I.; Merhi F.; Bauvois B.; Billard C.; Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa. Int J Oncol 2012,40(1),269-276","journal-title":"Int J Oncol"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.canlet.2010.10.016","volume":"300","author":"Yamamoto K.","year":"2011","unstructured":"Yamamoto K.; Ishikawa C.; Katano H.; Yasumoto T.; Mori N.; Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas. Cancer Lett 2011,300(2),225-234","journal-title":"Cancer Lett"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1080\/10428190701474332","volume":"48","author":"Quiney C.","year":"2007","unstructured":"Quiney C.; Billard C.; Faussat A-M.; Salanoubat C.; Kolb J-P.; Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells. Leuk Lymphoma 2007,48(8),1587-1599","journal-title":"Leuk Lymphoma"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/md10010242","volume":"10","author":"Liu C.L.","year":"2012","unstructured":"Liu C.L.; Lim Y.P.; Hu M.L.; Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs 2012,10(1),242-257","journal-title":"Mar Drugs"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.phymed.2012.05.010","volume":"19","author":"Eid S.Y.","year":"2012","unstructured":"Eid S.Y.; El-Readi M.Z.; Wink M.; Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine 2012,19(11),977-987","journal-title":"Phytomedicine"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5045\/br.2015.50.3.154","volume":"50","author":"Lardo M.","year":"2015","unstructured":"Lardo M.; Castro M.; Moiraghi B.; Rojas F.; Borda N.; Rey J.A.; Lazarowski A.; MDR1\/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia. Blood Res 2015,50(3),154-159","journal-title":"Blood Res"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1021\/jf301981n","volume":"60","author":"Lin L.C.","year":"2012","unstructured":"Lin L.C.; Yeh C.T.; Kuo C.C.; Lee C.M.; Yen G.C.; Wang L.S.; Wu C.H.; Yang W.C.; Wu A.T.; Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt\/beta-catenin function. J Agric Food Chem 2012,60(28),7031-7039","journal-title":"J Agric Food Chem"},{"key":"ref=124","volume":"7","author":"Bonifacio M.","year":"2012","unstructured":"Bonifacio M.; Rigo A.; Guardalben E.; Bergamini C.; Cavalieri E.; Fato R.; Pizzolo G.; Suzuki H.; Vinante F.; Alpha-bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with Imatinib and Nilotinib. PLoS One 2012,7(10)","journal-title":"PLoS One"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"12643","DOI":"10.1007\/s13277-016-5179-7","volume":"37","author":"Oaxaca D.M.","year":"2016","unstructured":"Oaxaca D.M.; Yang-Reid S.A.; Ross J.A.; Rodriguez G.; Staniswalis J.G.; Kirken R.A.; Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Tumour Biol 2016,37(9),12643-12654","journal-title":"Tumour Biol"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T08:02:03Z","timestamp":1581926523000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170596\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557519666190311095655","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}